Bayer plans to spend nearly $700 million to expand production capacity at its Wuppertal and Leverkusen sites in Germany, where it plans to manufacture its two experimental hemophilia A drugs. Both drugs, BAY 81-8973 and BAY 94-9027, are in late-stage trials. Bayer said the investment would create about 500 new jobs at the two sites by 2020.

Related Summaries